Prevalence, factors influencing and knowledge about adherence to lipid-lowering therapy among hyperlipidemia patients

N K Devaraj1, M Mohamed2, N Hussein2

  • 1Universiti Putra Malaysia, Department of Family Medicine, 43400,Serdang, Selangor, Malaysia. knavin@upm.edu.my.

Insights

High adherence to lipid-lowering therapy was observed in Malaysian patients with hyperlipidemia. Interventions should focus on identified non-adherent individuals to improve cardiovascular disease risk management.

Area of Science:

  • Cardiology
  • Public Health
  • Pharmacoeconomics

Background:

  • Hyperlipidemia is a major risk factor for cardiovascular disease.
  • Adherence to lipid-lowering therapy is often suboptimal.
  • Patient, therapy, socio-economic, and health system factors influence adherence.

Purpose of the Study:

  • To determine the prevalence of adherence to lipid-lowering therapy.
  • To identify factors contributing to non-adherence.
  • To assess knowledge of hyperlipidemia and its treatment among Malaysian patients.

Main Methods:

  • A cross-sectional survey was conducted in an urban primary care clinic.
  • Simple random sampling selected patients on lipid-lowering therapy for ≥ 1 year.
  • A self-administered questionnaire assessed adherence, reasons for non-adherence, and knowledge.

Main Results:

  • The adherence rate was 82.4% with a 90.7% response rate.
  • Common reasons for non-adherence included fear of side effects, polypharmacy, and external influences.
  • Non-adherence was associated with male gender, longer therapy duration, fewer follow-ups, and lower knowledge scores.

Conclusions:

  • The prevalence of adherence to lipid-lowering therapy was high among Malaysian hyperlipidemia patients.
  • Targeted interventions are needed for non-adherent patients to enhance treatment outcomes.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
482
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
6.0K
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
382
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
322
Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
1.6K